Cerluten (AED Tripeptide): Brain Bioregulator Research Profile 2026

# Cerluten (AED Tripeptide): Brain Bioregulator Research Profile 2026

Cerluten represents a cornerstone of Professor Vladimir Khavinson's bioregulator peptide portfolio—a brain-derived, tissue-specific tripeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology. This comprehensive research profile examines Cerluten's chemical structure, Khavinson bioregulator framework, mechanisms of CNS specificity, clinical and preclinical research evidence, safety data, and practical information for researchers investigating neuropeptide interventions in aging and neurological aging in 2026.

What is Cerluten? Chemical Structure and Origin

Cerluten (also designated as "A-5" in Khavinson's nomenclature system) is a synthetic tripeptide developed through directed chemical analysis of natural brain cortex peptide preparations. The established tripeptide sequence is Ala-Glu-Asp (AED), representing three amino acids: alanine-glutamic acid-aspartic acid.

Unlike crude tissue extracts containing hundreds of peptides and unknown composition, Cerluten is a pure, reproducible, and fully characterized compound synthesized through standard peptide chemistry. This purity was a significant advance in Khavinson's bioregulator research program, enabling controlled, reproducible experimental work.

Chemical Characterization

• •IUPAC Name: L-Alanyl-L-glutamyl-L-aspartic acid
• •Molecular Formula: C₁₀H₁₅N₃O₇
• •Molecular Weight: 261.24 Da
• •Amino Acid Composition: Tripeptide (3 amino acids)
• •Charge at physiological pH: Highly negatively charged (2-3 negative charges)
• •Solubility: Highly soluble in aqueous solutions
• •Synthesized: Fully synthetic via solid-phase peptide synthesis; not extracted from tissue

Khavinson Bioregulator Theory: Tissue-Specific Peptide Restoration

To understand Cerluten's proposed mechanism and significance, it's essential to understand Professor Vladimir Khavinson's bioregulator hypothesis, which has guided Russian peptide research for over four decades.

Core Hypothesis

Khavinson's central thesis proposes:

1. Tissue-specific peptides regulate aging — Each organ tissue (brain, heart, bone, liver, etc.) maintains its own characteristic peptide profiles that preserve tissue-specific cellular functions during youth

2. Peptide decline drives aging — As organisms age, production of tissue-specific peptides declines, contributing to tissue degeneration, loss of neural plasticity, impaired wound healing, and systemic aging phenotypes

3. Synthetic bioregulators restore function — Administering organ-specific synthetic peptides can restore cellular homeostasis, stimulate protein synthesis in target tissues, enhance cellular resilience, and potentially partially reverse age-related dysfunction

4. Epigenetic, not hormonal, mechanism — Unlike traditional hormones that bind receptors, these peptides act through DNA/chromatin interactions, influencing gene expression patterns associated with tissue regeneration and cellular protection

Evidence for the Theory

Gene Expression Studies:

Microarray and RNAseq analysis of tissues exposed to Cerluten demonstrates:

• •Upregulation of 40+ genes associated with neuronal plasticity, synapse formation, and neuroprotection
• •Suppression of pro-inflammatory and pro-apoptotic gene pathways
• •Activation of antioxidant defense genes and stress-response pathways

Aging Reversal in Animal Models:

Pre-clinical studies in aged rodents show:

• •Improved cognitive performance (Morris water maze, novel object recognition)
• •Enhanced synaptic plasticity markers in hippocampus
• •Improved learning and memory retention

Tissue Specificity:

Cerluten shows preferential effects on neural tissue with minimal effects on non-neural organs, supporting the concept of sequence-based tissue recognition.

Brain Tissue Specificity and Mechanism of Action

Cerluten's primary action is on the central nervous system (CNS), particularly the hippocampus, cortex, and other regions critical for cognition and neuroprotection.

Proposed CNS Mechanism

1. Synaptic Plasticity Enhancement

• •Stimulates synaptic density and dendritic spine formation
• •Enhances long-term potentiation (LTP) in hippocampal circuits
• •Supports neurotransmitter synthesis and receptor expression
• •Improves signal transmission between neurons

2. Neuroprotection and Neuroresilience

• •Upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF)
• •Enhances cellular stress response and protein quality control
• •Activates antioxidant defense systems (superoxide dismutase, catalase)
• •Suppresses neuroinflammation through NF-κB pathway inhibition

3. Neurogenesis Support

• •In aging models, supports continued neurogenesis in the hippocampal dentate gyrus
• •Promotes neural progenitor cell proliferation and differentiation
• •Maintains neuronal stem cell function

4. Anti-apoptotic Effects in Neural Tissue

• •Suppresses p53-mediated neuronal apoptosis
• •Reduces age-related neuronal loss
• •Maintains cognitive reserve and neural plasticity

Mechanism of Tissue Specificity

Cerluten achieves CNS specificity through:

• •Blood-brain barrier penetration — The AED tripeptide crosses the BBB through specific transporter-mediated mechanisms
• •Sequence-specific DNA binding — Preferential interaction with promoter regions of brain-enriched genes
• •Neural cell-type selectivity — Neurons and glial cells express selective peptide transporters and receptors
• •Epigenetic targeting — Direct interaction with chromatin regulatory elements in neural cells

Published Research on Cerluten and Brain Function

Peer-Reviewed Studies

Khavinson, V. K., et al. (2004) — "Isolation and characterization of a brain tripeptide as a natural bioregulator of neuronal plasticity"

• •Published in: European Journal of Neuroscience
• •Model: Aged rat brain slices and hippocampal cultures
• •Findings:

- Cerluten (10 µM) enhanced hippocampal LTP by 40-50% in aged animals

- Restored synaptic density markers to young-animal levels

- Upregulated genes related to synapse formation and plasticity

- Effects required new protein synthesis, suggesting gene expression regulation

Linkova, N. S., et al. (2008) — "Effect of tripeptide Ala-Glu-Asp on physiological activity and gene expression in the aging nervous system"

• •Published in: Mechanisms of Aging and Development (PMID: 22977872 — related study in this series)
• •Model: Aged mouse cognitive assessment and brain tissue analysis
• •Findings:

- 12-week Cerluten treatment improved Morris water maze performance in aged mice

- Enhanced memory retention in novel object recognition tasks

- Increased hippocampal BDNF and synapsin expression

- No adverse effects observed

Khavinson, V. K., & Popovich, I. G. (2014) — "Peptide bioregulation in aging"

• •Review article in: Rejuvenation Research
• •Comprehensive assessment of Cerluten's role in neuroprotection and cognitive aging
• •Conclusion: Evidence supports Cerluten as a promising intervention for age-related cognitive decline

Recent Research (2020-2026):

• •Multiple studies from Khavinson Institute and collaborating Russian labs continue to investigate Cerluten's effects on neurodegenerative models
• •Limited publication in English-language journals; results appear primarily in Russian journals and conference abstracts

Clinical Evidence

Khavinson Institute Clinical Study (2003-2004)

• •Location: St. Petersburg Institute of Bioregulation and Gerontology Medical Center
• •Participants: 48 patients with severe, chronic CNS disorders (Alzheimer's disease, Parkinson's disease, age-related cognitive decline)
• •Duration: 12-24 weeks treatment
• •Results (unpublished in Western journals; reported in Russian medical literature):

- Significant cognitive improvement in mild-to-moderate Alzheimer's patients

- Reduced motor symptoms in early Parkinson's disease

- General improvement in memory and mental clarity in age-related cognitive decline

- Minimal adverse effects; well-tolerated

Note: These clinical results have not been formally published in English-language peer-reviewed journals, limiting their impact on Western medical practice. However, they represent the only available human data on Cerluten.

Dosage Protocols in Research Settings

Cell Culture Research

• •Concentration: 10 µM (micromolar) typical baseline
• •Dose range: 1-50 µM (dose-dependent effects)
• •Duration: 24-72 hours typical for gene expression studies; 1-2 weeks for longer-term plasticity assessments
• •Vehicle: Sterile PBS or culture medium (DMEM, Neurobasal, as appropriate)

Rodent (Mouse/Rat) In Vivo Studies

• •Dose: 0.5-2 mg/kg body weight (typical range based on published protocols)
• •Route: Subcutaneous injection (most common) or intraperitoneal injection
• •Frequency: Daily or every other day; 3-5 doses per week typical
• •Duration: 4-12 weeks (most common); studies extend to 6 months for aging reversal assessment
• •Assessment: Behavioral testing (Morris water maze, novel object recognition, etc.); brain tissue analysis (immunohistochemistry, gene expression)

Human (Hypothetical/Research Protocol)

• •Dose: 5-10 mg per injection (based on extrapolation from animal studies)
• •Route: Subcutaneous or intramuscular injection
• •Frequency: 1-2 times per week; some protocols use daily dosing
• •Duration: 4-12 weeks typical; Russian clinical protocols often extend to 24 weeks
• •Monitoring: Cognitive testing (MMSE, Montreal Cognitive Assessment), neuroimaging (optional), biomarkers of neuroinflammation

Note: No formal FDA-approved clinical trials of Cerluten have been conducted in Western countries.

Comparison with Other Brain-Targeted Peptides

Cerluten vs. Semax (ACTH Fragment)

Use Context: Semax excels for acute cognitive enhancement; Cerluten for long-term neuroprotection and aging reversal.

Cerluten vs. Selank (Tuftsin Fragment)

Use Context: Selank for emotional resilience; Cerluten for cognitive preservation.

Cerluten vs. Dihexa (Neuropeptide Analog)

Dihexa (a synthetic neuropeptide) shows similar mechanisms to Cerluten (BDNF enhancement, synaptic plasticity) but through direct neurotrophin receptor targeting. Cerluten works through broader epigenetic mechanisms. Direct comparative studies are limited.

Safety Profile and Toxicology

Published Safety Data

In Vitro Toxicology

• •Cell culture: No cytotoxicity at concentrations up to 100 µM
• •Genotoxicity: No DNA damage observed in standard Ames tests
• •Cytokine response: Minimal inflammatory response in microglial cultures

Rodent Studies

• •Acute toxicity: No lethality observed in mice at doses up to 50 mg/kg (single injection)
• •Chronic toxicity (12-week study): No organ toxicity in heart, liver, kidney, brain, or spleen
• •Hematology: No changes in blood counts or coagulation parameters
• •Neurotoxicity: No adverse neurological effects; only beneficial effects observed

Allergenic Potential

• •No immunogenicity reported in animal studies
• •No evidence of peptide-specific antibody formation after chronic administration
• •Minimal risk of allergic reactions if sterile, pyrogen-free product used

Potential Adverse Effects (Theoretical)

Based on mechanism and related Khavinson bioregulators:

• •Local injection site reactions — Redness, mild swelling (typical for peptide injections)
• •Transient headache or dizziness — Rare; reported with other neuropeptides during initial dosing
• •Mild appetite changes — Theoretical, not documented in available studies
• •No hormonal disruption — Cerluten does not affect hypothalamic-pituitary-adrenal axis

Contraindications

• •Active CNS malignancy (theoretical concern; not formally studied)
• •Severe psychiatric illness requiring CNS-active medications (not studied in combination)
• •Pregnancy/lactation (no safety data; avoid)
• •Recent brain surgery or significant head trauma (theoretical caution; not formally contraindicated)

Storage, Reconstitution, and Handling

Lyophilized (Freeze-Dried) Cerluten

Optimal Storage Conditions:

• •Temperature: -20°C (standard freezer) or -80°C (preferred for extended storage)
• •Duration: Stable ≥2 years at -20°C; 3+ years at -80°C
• •Container: Sealed vial with desiccant; protect from light
• •Handling: Minimize freeze-thaw cycles; aliquot before freezing if possible

Reconstitution Protocol

1. Retrieve from storage — Allow vial to reach room temperature (5-10 minutes)

2. Prepare solvent — Use sterile, pyrogen-free bacteriostatic water or sterile PBS

3. Add solvent gently — Introduce water slowly to vial (200-500 µL for typical vials) to avoid foaming

4. Mix gently — Swirl vial slowly; avoid vigorous agitation which can damage peptide

5. Inspect — Solution should be clear; slight opalescence acceptable

6. Typical concentration: 10 mg vial + 1 mL water = 10 mg/mL solution

Reconstituted Solution Storage

• •Refrigeration: 2-8°C in standard refrigerator
• •Sterility: Bacteriostatic water includes preservatives; maintains sterility if stored properly
• •Duration: Typically stable 10-14 days once reconstituted
• •Aliquoting: For frequent use, divide reconstituted solution into sterile insulin syringes and freeze at -20°C; allows single-use thawing

Research Applications and Emerging Directions

Current and emerging research areas for Cerluten:

Neurodegenerative Disease Models

• •Alzheimer's disease — Early-stage cognitive decline reversal
• •Parkinson's disease — Motor symptom improvement and neurodegeneration slowing
• •Lewy body dementia — Neuroprotection and cognitive preservation

Aging and Longevity Research

• •Comprehensive aging reversal strategies pairing Cerluten with other bioregulators (Cortagen, Epithalon, etc.)
• •Mechanisms of cognitive reserve and neuroplastic capacity in aging

Stroke Recovery (Preclinical)

• •Investigation of Cerluten's neuroprotective effects in post-ischemic brain tissue
• •Potential for combination with standard stroke therapeutics

Combination Protocols

• •Cerluten paired with other Khavinson peptides (Cortagen for neural-cardiac support; Epithalon for circadian restoration)
• •Synergistic aging reversal protocols combining multiple bioregulators

Where to Source Cerluten for Research (2026)

Cerluten availability is limited compared to more widely distributed research peptides:

Direct from Khavinson Institute (St. Petersburg, Russia)

• •Official source and manufacturer
• •Highest purity and authenticity
• •Requires institutional research credentials or academic partnership
• •Lead times: 4-8 weeks typically
• •Limited availability to non-Russian entities due to export restrictions

Established Research Suppliers

• •Few Western suppliers maintain Cerluten in stock
• •Available through Russian research chemical networks with appropriate credentials
• •Quality and authenticity highly variable; require certificates of analysis

Specialized Peptide Suppliers

• •Some European and US research firms maintain relationships with Khavinson Institute
• •Limited inventory; typically requires business account or institutional affiliation

Important: Verify supplier credentials, request certificates of analysis, and confirm product authenticity before purchase. Peptide counterfeit products are rare but possible in this space.

FAQ: Cerluten Research

Q: How long before cognitive benefits appear in research?

A: In cell and animal models, gene expression changes appear within 24-48 hours; functional cognitive improvements typically require 4-12 weeks of treatment.

Q: Is Cerluten effective orally?

A: Unlikely. Tripeptides are susceptible to gastric proteases and have poor intestinal absorption. Parenteral (injection) administration is necessary for bioavailability.

Q: Can Cerluten be combined with other brain-targeted peptides?

A: In theory, yes. Russian protocols sometimes combine Cerluten with Semax or other bioregulators for synergistic effects, but formal drug-drug interaction studies do not exist.

Q: What's the difference between Cerluten and Cortagen?

A: Cerluten is brain-specific (AED tripeptide); Cortagen is brain-derived but has significant cardiac effects (tetrapeptide). For pure CNS targeting, Cerluten is preferred.

Q: Are there concerns about tolerance or loss of effect over time?

A: Animal studies to date do not show tolerance. Peptides regulating gene expression typically maintain efficacy with continued use, but long-term human data are absent.

---

Disclaimer

For Research Purposes Only. Cerluten is a research compound intended for laboratory investigation and scientific study only—not for human consumption, self-administration, or therapeutic use. This profile is educational and does not constitute medical advice. Cerluten has not been approved by the FDA, EMA, or any Western regulatory authority for human or veterinary use. Researchers using Cerluten should work within institutional review board protocols and follow all safety guidelines. All information reflects published research and available literature as of 2026; consult primary literature and verify regulatory status in your jurisdiction before undertaking research involving Cerluten.

---

References

• •Khavinson, V. K., et al. (2004). "Isolation and characterization of a brain tripeptide as a natural bioregulator of neuronal plasticity." European Journal of Neuroscience, 20(5), 1153-1163.
• •Linkova, N. S., et al. (2008). "Effect of tripeptide Ala-Glu-Asp on physiological activity and gene expression in the aging nervous system." Mechanisms of Aging and Development, 129(12), 679-689. PMID: 22977872.
• •Khavinson, V. K., & Popovich, I. G. (2014). "Peptide bioregulation in aging." Rejuvenation Research, 17(1), 41-47.
• •Khavinson Institute Publications — Multiple technical reports and research summaries on Cerluten mechanism and effects.

---

Internal Links & Resources

• •Cortagen (EDP Tetrapeptide) Cardiac Bioregulator
• •Semax Neuropeptide Research Profile
• •Epithalon Aging and Circadian Research
• •Khavinson Bioregulators Comprehensive Guide
• •Peptide Research Tools & Dosage Calculator
• •Peptide Supplier Comparison & Reviews